HDAC9 and T-cell non-Hodgkin lymphoma: In EBV-positive lymphomas, including T-cell lymphomas such as extranodal NK/T-cell lymphoma and systemic chronic active EBV disease, the combination of nanatinostat, a class I selective HDAC inhibitor, and valganciclovir shows promising efficacy [38].